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Lead absorption increases blood pressure,
especially systolic blood pressure, at blood
lead levels as low as 5 µg/dL (1,2). Little is
known, however, about genetic variation in
risk of elevated blood pressure from lead. In
particular, two polymorphic genes known to
modify the toxicokinetics of lead—those for
the vitamin D receptor (VDR) (3–5) and δ -
aminolevulinic acid dehydratase (ALAD)
(5–17)—could influence the effect of lead
on blood pressure and hypertension. 
ALAD is a principal erythrocytic binding
site for lead, and such binding differs for the
three isoforms of the ALAD protein (17).
Thus, the polymorphism could inﬂuence the
effect of lead on blood pressure by, for exam-
ple, modifying the deposition of lead at the
critical cellular or molecular targets through
which lead acts to cause elevations in blood
pressure. VDR genotype is also of particular
interest not only because it has been impli-
cated to modify the absorption of lead and
the uptake and release of lead from bone
(3,4), but also because alterations in calcium
metabolism have been implicated in the risk
of elevations in blood pressure and essential
hypertension. These alterations include
such factors as calcium intake, calcium
absorption, bone calcium metabolism,
serum calcium levels, and cytosolic free cal-
cium (18–21). Vasoactive, neural, hor-
monal, and renal effects of calcium also play
a role in blood pressure regulation (22,23).
Polymorphisms in the VDR gene could
thus have a direct influence on blood pres-
sure and hypertension risk, independent of
lead, but this possibility has not been
investigated. 
The prevalence of the ALAD and VDR
polymorphisms differs by race/ethnicity.
Although reported prevalence estimates dif-
fer from study to study, approximately
15–25% of Australian, U.S., and European
whites are homozygous for the absence of
the BsmI restriction site (BB genotype); in
contrast, 0–13% of African Americans and
1–3% of Asians have the BB genotype
(24–28). Similarly, the prevalence of the
ALAD2 allele varies by race/ethnicity.
Approximately 20% of Caucasians, 5–10%
of Asians, and 0–2% of Africans or African
Americans have the allele (5,7,9,10). 
Here we we report a cross-sectional evalu-
ation of the relations among the two poly-
morphic genes, three lead dose measures, and
blood pressure and hypertension status in
798 Korean lead workers and 135 controls
without occupational exposure to lead. 
Materials and Methods
Study overview and design. The results pre-
sented here are a cross-sectional analysis of
data from the ﬁrst year of a 3-year longitudi-
nal study of the health effects of occupa-
tional inorganic lead exposure (29,30).
Enrollment began in October 1997 with the
first of three annual evaluations for each
study subject. The current report is an analy-
sis of data obtained during the first study
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Evidence suggests that lead and selected genes known to modify the toxicokinetics of lead—
namely, those for the vitamin D receptor (VDR) and δ -aminolevulinic acid dehydratase
(ALAD)—may independently inﬂuence blood pressure and hypertension risk. We report the rela-
tions among ALAD and VDR genotypes, three lead dose measures, and blood pressure and hyper-
tension status in 798 Korean lead workers and 135 controls without occupational exposure to
lead. Lead dose was assessed by blood lead, tibia lead measured by X-ray ﬂuorescence, and dimer-
captosuccinic acid (DMSA)-chelatable lead. Among lead workers, 9.9% (n = 79) were heterozy-
gous for the ALAD2 allele, and there were no ALAD2 homozygotes; 11.2% (n = 89) had at least
one copy of the VDR B allele, and 0.5% (n = 4) had the BB genotype. In linear regression models
to control for covariates, VDR genotype (BB and Bb vs. bb), blood lead, tibia lead, and DMSA-
chelatable lead were all positive predictors of systolic blood pressure. On average, lead workers
with the VDR B allele, mainly heterozygotes, had systolic blood pressures that were 2.7–3.7 mm
Hg higher than did workers with the bb genotype. VDR genotype was also associated with dias-
tolic blood pressure; on average, lead workers with the VDR B allele had diastolic blood pressures
that were 1.9–2.5 mm Hg higher than did lead workers with the VDR bb genotype (p = 0.04).
VDR genotype modiﬁed the relation of age with systolic blood pressure; compared to lead work-
ers with the VDR bb genotype, workers with the VDR B allele had larger elevations in blood
pressure with increasing age. Lead workers with the VDR B allele also had a higher prevalence of
hypertension compared to lead workers with the bb genotype [adjusted odds ratio (95% confi-
dence interval) = 2.1 (1.0, 4.4), p = 0.05]. None of the lead biomarkers was associated with dias-
tolic blood pressure, and tibia lead was the only lead dose measure that was a signiﬁcant predictor
of hypertension status. In contrast to VDR, ALAD genotype was not associated with the blood
pressure measures and did not modify associations of the lead dose measures with any of the
blood pressure measures. To our knowledge, these are the ﬁrst data to suggest that the common
genetic polymorphism in the VDR is associated with blood pressure and hypertension risk. We
speculate that the BsmI polymorphism may be in linkage disequilibrium with another functional
variant at the VDR locus or with a nearby gene. Key words: δ -aminolevulinic acid dehydratase,
blood pressure, hypertension, lead, polymorphisms, vitamin D receptor, X-ray fluorescence.
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October 1997 and 19 August 1999. The
study was reviewed and approved by institu-
tional review boards at the Johns Hopkins
School of Hygiene and Public Health and
the Soonchunhyang University School of
Medicine. 
Study population. Participation in the
study was voluntary, and all participants pro-
vided written, informed consent. Subjects
were paid approximately $30 for their partic-
ipation. Lead workers were recruited from 24
different lead-using facilities, with participa-
tion in most facilities exceeding 80% (29).
Retired workers from three facilities who had
received medical surveillance services by
Soonchunhyang University for several years
were also recruited to participate in the study.
Routine, governmentally mandated industrial
hygiene sampling revealed that the study
plants did not have significant amounts of
other heavy metals such as cadmium.
Controls without occupational lead exposure
were recruited from an air conditioner assem-
bly plant that did not use lead or other heavy
metals and from hourly-wage workers of
Soonchunhyang University. 
Data collection. Data collection methods
have been reported previously (29). In brief,
data were collected either at the Institute of
Industrial Medicine at Soonchunhyang
University in Chonan or on the premises of
the study’s lead-using facilities. The following
were collected or measured on all study sub-
jects: a standardized interview for demograph-
ics, medical history, and occupational history;
a neurobehavioral test battery consisting of
examiner-administered tests; blood pressure;
peripheral vibration threshold and pinch and
grip strength; a 10-mL blood specimen taken
by venipuncture that was stored at –70°C as
whole blood, plasma, and red blood cells; a
spot urine sample; tibia lead concentration
assessed by X-ray ﬂuorescence (XRF); and a
urine sample collected for 4 hr after oral
administration of dimercaptosuccinic acid
(DMSA) (in lead workers only). Blood pres-
sure—systolic and ﬁfth Korotkoff diastolic—
was measured using a Hawksley random zero
sphygmomanometer (Hawksley, Sussex,
England) according to the Johns Hopkins
Welch Center for Prevention, Epidemiology,
and Clinical Trials protocol. Three measure-
ments, using an appropriately sized cuff, were
taken 5 min apart with the subject sitting by a
physician trained in the method. 
Laboratory methods. We assayed hemo-
globin by the cyanmethemoglobin method
(Model Ac-T 8; Beckman Coulter, Inc.,
Fullerton, CA, USA), and measured hemat-
ocrit by the capillary centrifugation method
(31). We measured urinary creatinine from
the 4-hr urine sample after oral administra-
tion of DMSA, using the Sigma kit (St.
Louis, MO, USA) and a Beckman DU-7
spectrophotometer (Beckman Instruments,
Inc., Fullerton, CA, USA) (32). To ensure
that DMSA in urine did not interfere with
the creatinine assay, we spiked 12 urine sam-
ples with 15 mg/dL of a creatinine standard
(Sigma), and compared the assay results with
expected values. A scatterplot of the relation
of the measured to the expected values had a
Pearson’s r of 0.998, a slope of 1.0, and an
intercept of 0, within error. There was also
no evidence that DMSA interfered with cre-
atinine excretion in vivo, because the mea-
sured 4-hr creatinine clearances were within
the range of normal expected values for both
males and females [determined by multiply-
ing published values for 24-hr creatinine
excretion (milligrams per kilogram) by the
weight of study subjects and dividing to
adjust for a 4-hr collection period].
We measured zinc protoporphyrin levels
with a portable hematoﬂuorimeter (33) and
blood lead levels with a Zeeman background-
corrected atomic absorption spectrophotome-
ter (Z-8100 model; Hitachi, Tokyo, Japan)
using the standard addition method of the
National Institute of Occupational Safety and
Health (34) at Soonchunhyang University
Institute of Industrial Medicine, a certified
reference laboratory for lead in Korea. We
assessed tibia lead, in units of micrograms lead
per gram bone mineral (hereafter referred to
as µg/g), with a 30-min measurement at the
left mid-tibial shaft using 109Cd-induced K-
shell XRF, as previously described (30,35,36).
XRF can provide negative point estimates of
bone lead concentrations; however, all point
estimates were retained in the statistical analy-
ses, including negative values, because this
method minimizes bias and does not require
censoring of data (37). 
We used 4-hr urinary lead excretion after
oral administration of 10 mg/kg DMSA to
measure DMSA-chelatable lead (38). We
measured urine lead levels in the laboratories
of the Wadsworth Center at the New York
State Department of Health, Albany, New
York. We determined urinary lead concen-
trations by electrothermal atomization
atomic absorption spectrometry (Model
4100ZL; PerkinElmer, Norwalk, CT, USA)
using previously published methods (39).
Urinary lead excretion was highly correlated
with lead excretion adjusted for differences,
generally small, in urine collection times
(Pearson’s r = 0.98), so we presented only
the unadjusted data.
ALAD and VDR genotyping. We com-
pleted ALAD and VDR genotyping on 795
and 798 lead workers, respectively, and 135
nonexposed control subjects. VDR genotyp-
ing was completed using previously pub-
lished methods (4,40). In brief, we extracted
genomic DNA from whole blood using the
QIAamp Blood Kit (QIAGEN, Hilden,
Germany), and the BsmI polymorphic site in
intron 8 was ampliﬁed by polymerase chain
reaction (PCR) using the primers originating
in exon 7 (primer 1: 5´-CAACCAAGAC-
TACAAGTACCGCGTCAGTGA-3´) and
intron 8 (primer 2: 5´-AACCAGCGGGAA-
GAGGTCAAGGG-3´). Subjects homozy-
gous for the presence of the BsmI restriction
site are designated bb, heterozygotes are des-
ignated Bb, and those homozygous for the
absence of the site are designated BB.
We used a modiﬁed PCR-based protocol
for ALAD genotyping, as described previously
(6–9). The ALAD gene has two alleles,
ALAD1 and  ALAD2, producing three
isozymes, ALAD1-1, ALAD1-2, and ALAD2-
2. In brief, the initial ampliﬁcation, using 3´
and 5´ oligonucleotide primers [(5´-AGACA-
GACATTAGCTCAGTA-3´) and (5´-
GGCAAAGAACACGTCCATTC-3´)]
generates a 916 base-pair fragment. A second
round of ampliﬁcation using a pair of nested
primers (ﬂanking DNA sequence kindly pro-
vided by J. Wetmur), sequences (5´-
CAGAGCTGTTCCAAC-AGTGGA-3´)
and (5´-CCAGCACAATGTGGGAGTGA-
3´), respectively, and generates an 887 base-
pair fragment. The amplified fragment was
cleaved at the diagnostic Msp1 site, present
only in the ALAD2 allele.
Statistical analysis. The primary goals of
the analysis were to examine relations of
ALAD and VDR genotype with systolic
blood pressure, diastolic blood pressure, and
hypertension status, controlling for covari-
ates, and to determine if ALAD and VDR
genotype modified the relations of age,
blood lead, tibia lead, and DMSA-chelat-
able lead with systolic blood pressure, dias-
tolic blood pressure, or hypertension status. 
We used linear regression to model sepa-
rately systolic and diastolic blood pressure,
controlling for confounding variables, using
SAS software programs (SAS Institute, Inc.,
Cary, NC, USA). First, we compared lead
workers to controls without occupational lead
exposure. Next, we evaluated associations of
the lead dose measures and genetic factors in
the lead workers only. Covariates examined in
linear regression models included age, gender,
creatinine clearance (4 hr), hemoglobin,
hematocrit, weight, height, body mass index,
job duration, tobacco and alcohol consump-
tion (never, previous, and current use for
each), lifetime tobacco consumption (in pack-
years), and cumulative lifetime alcohol drinks
in current alcohol users [divided into quartiles
of lifetime cumulative drinks (one glass of
beer or wine or one shot of distilled spirits)].
Covariates were retained in the ﬁnal regres-
sion models if they were either a signiﬁcant
predictor of blood pressure or a confounder of
the relations between predictor variables and
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changes in the coefﬁcients of predictor vari-
ables after inclusion of potential confounding
variables). To evaluate effect modiﬁcation by
ALAD and VDR genotype, we added cross-
product terms of the genetic factors and the
lead dose measures and age to the models of
systolic and diastolic blood pressure, one
cross-product term at a time. 
We deﬁned hypertension as systolic blood
pressure > 160 mm Hg or diastolic blood
pressure > 96 mm Hg or a patient’s currently
taking medications for high blood pressure, to
increase the speciﬁcity of the categorization
and to be consistent with prior research
(2,41). We evaluated associations between
ALAD and VDR genotype and hypertension
in contingency tables using odds ratios and
95% exact conﬁdence limits calculated with
Epi Info version 6.04b (Centers for Disease
Control and Prevention, Atlanta, GA). We
used logistic regression to model hypertension
status, controlling for confounding variables,
after evaluating the potential covariates
described above for systolic and diastolic
blood pressure. We added cross-product
terms to the logistic regression models of
hypertension one at a time to evaluate effect
modiﬁcation by ALAD or VDR genotype. 
Results
Demographics and dose measures. Compared
to nonexposed controls, lead-exposed sub-
jects were older (40.5 vs. 34.5 years), had
lower education levels (49.9% vs. 19.2% did
not complete high school), and had a lower
proportion of male subjects [79.4% vs.
91.9% (Table 1)]. The majority of both non-
exposed and exposed subjects were current
users of tobacco and alcohol products. There
was a wide range of blood lead (4–86 µg/dL),
tibia lead (–7–338 µg/g), and DMSA-chelat-
able lead (4.8–2,103 µg) levels among lead
workers (Table 1). The corresponding values
among nonexposed control subjects were low
(Table 1). 
Prevalence and associations of genotypes.
Among lead workers, 9.9% (n = 79) were
heterozygous for the ALAD2 allele and there
were no ALAD2 homozygotes. A total of
11.2% (n = 89) had at least one copy of the
VDR B allele and 0.5% (n = 4) had the BB
genotype. The corresponding values for non-
exposed controls were 8.1% (n = 11) for the
ALAD2 allele and 8.9% (n = 12) and 0.7%
(n = 1) for one and two copies of the VDR B
allele, respectively. Because of the small num-
ber of subjects with the BB genotype, they
were combined with the heterozygous variant
allele carriers for all subsequent analysis.
There were no differences in age, job
duration, lead dose measures, or systolic or
diastolic blood pressure by ALAD genotype.
In contrast, subjects with the VDR B allele
were older, had higher DMSA-chelatable lead
levels, and had higher systolic and diastolic
blood pressures (all p-values < 0.05; Table 2).
Analysis comparing lead workers and
controls. Compared to lead workers, control
subjects without occupational exposure to
lead evidenced no average difference in sys-
tolic or diastolic blood pressure after
adjustment for age, sex, body mass index,
antihypertensive medication use, current
alcohol use, blood lead, and ALAD and
VDR genotypes (data not shown). There was
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Table 1. Description of study subjects, October 1997–August 1999, Republic of Korea.
Lead-exposed subjects (n = 798) Nonexposed controls (n = 135)
Characteristic Mean SD Range Mean SD Range
Age, years 40.5 10.1 17.8–64.8 34.5 9.1 22.0–60.2
Lead work job duration, years 8.2 6.5 0.1–36.2 NA
Height, cm 164.7 8.1 127.8–186.0 167.9 6.2 148.0–183.4
Weight, kg 62.5 9.1 37.4–92.7 66.9 9.0 48.0–93.5
Body mass index, kg/cm2 23.0 3.0 15.7–34.2 23.7 2.8 18.5–30.1
Blood lead, µg/dL 32.0 15.0 4–86 5.3 1.8 2–10 
Tibia lead, µg Pb/g bone mineral 37.2 40.4 –7–338 5.8 7.0 –11–27
DMSA-chelatable lead, µga 186.0 208.4 4.8–2,103 NA
Hemoglobin, g/dL 14.2 1.4 6.5–17.9 15.3 1.2 11.1–18.2
Creatinine clearance, 4-hr, mL/min 114.3 33.9 11.2–351.6 NA
Educational level, n (%)
Lower school (≤ 6 years)  183 (23.0) 10 (7.4)
Some middle school (7–8 years) 29 (3.6) 3 (2.2)
Middle school graduate (9 years) 155 (19.4) 12 (8.9)
Some high school (10–11 years) 31 (3.9) 1 (0.7)
High school graduate (12 years) 335 (42.0) 93 (68.9)
One or two years college (13–14 years) 37 (4.6) 11 (8.1)
College graduate or more 27 (3.3) 5 (3.7)
Missing 1 (< 0.1) 0 (0.0)
Sex, male, n (%) 634 (79.4) 124 (91.9)
Tobacco use, n (%)
Never 254 (31.9) 35 (25.9)
Current use 455 (57.1) 87 (64.4)
Past use 88 (11.0) 13 (9.6)
Alcohol use, n (%)
Never 231 (29.0) 31 (23.0)
Current use 518 (65.0) 95 (70.4)
Past use 48 ( 6.0) 9 (6.7)
NA, not applicable. The 4-hr urine collection was performed only in subjects who received DMSA. 
aDMSA-chelatable lead (µg) was estimated as 4-hr urinary lead excretion after oral administration of 10 mg/kg DMSA, in lead-exposed subjects only (784 subjects completed the urine
collection). 
Table 2. Selected study variables (mean ± SD) by gene status in 798 lead-exposed subjects, October
1997–August 1999, Republic of Korea.
ALAD genotype (n = 795) VDR genotype (n = 798)
Characteristic 1-1 1-2 bb Bb or BB
Number (%) 716 (90.1) 79 (9.9) 709 (88.8) 89 (11.2)
Age, years 40.5 ± 10.2 40.1 ± 9.7 40.2 ± 10.0* 42.7 ± 10.3*
Job duration, years 8.2 ± 6.6 8.2 ± 5.8 8.4 ± 6.6 7.2 ± 5.6
Blood lead, µg/dL 31.7 ± 14.9 34.2 ± 15.9 31.6 ± 14.8 34.8 ± 16.1
Tibia lead, µg/g 37.5 ± 40.6 31.4 ± 29.5 37.1 ± 41.2 38.1 ± 33.5
DMSA-chelatable lead, µg 180.3 ± 181.2 161.7 ± 143.0 173.5 ± 176.8* 217.2 ± 179.7*
Systolic blood pressure, mm Hg 123.4 ± 16.5 122.3 ± 14.5 122.6 ± 15.5* 129.1 ± 20.6*
Diastolic blood pressure, mm Hg 75.9 ± 11.9 73.9 ± 12.5 75.3 ± 11.7* 79.4 ± 13.5*
*p < 0.05 comparing VDR Bb or BB to VDR bb.no signiﬁcant association of hypertension sta-
tus by current occupational lead exposure sta-
tus (lead workers vs. controls without
occupational exposure to lead), in crude
[odds ratio (OR) (95% CI) = 0.7 (0.4, 1.3)]
or adjusted analyses controlling for age, sex,
body mass index, current alcohol use, and
ALAD and VDR genotype [OR (95% CI) =
1.8 (0.9, 3.9)]. In controls, there was no
effect modiﬁcation by ALAD or VDR geno-
type on the relations of blood lead or tibia
lead with the blood pressure measures, but
the numbers of controls with the less preva-
lent genotypes were small (data not shown).
Predictors of systolic blood pressure. In
linear regression models in lead workers only,
VDR genotype (BB and Bb vs. bb), blood
lead, tibia lead, and DMSA-chelatable lead
were all positive predictors of systolic blood
pressure, controlling for age (linear and qua-
dratic terms), sex, body mass index, antihy-
pertensive medication use, and cumulative
lifetime alcoholic drinks (divided into quar-
tiles) (Table 3). In the model with tibia lead
(model 1, Table 3), adding blood urea nitro-
gen to the model increased the β coefﬁcient
for VDR genotype to 3.732 (p = 0.02). On
average, lead workers with the VDR B allele
had systolic blood pressure that was 2.7–3.7
mm Hg higher than did workers with the bb
genotype (depending on the model). Models
in which two lead dose measures were
included at a time suggested that DMSA-
chelatable lead was the best predictor of sys-
tolic blood pressure (models 4 and 5, Table
3). Neither ALAD nor VDR genotype was
associated with systolic blood pressure in lin-
ear regression models with controls only, but
there were only 11 and 13 controls with the
ALAD2 or VDR B alleles, respectively.
VDR genotype modiﬁed the relation of
age with systolic blood pressure (model 6,
Table 3 and Figure 1). Lead workers with
the VDR B allele had larger elevations in
blood pressure with increasing age than did
lead workers with the VDR bb genotype.
These elevations in blood pressure were also
observed at younger ages. In contrast, ALAD
genotype, VDR genotype, and age did not
modify the relations of blood lead, tibia lead,
DMSA-chelatable lead, sex, body mass index,
or job duration with systolic blood pressure. 
Predictors of diastolic blood pressure. On
average, lead workers with VDR BB or Bb
genotype had diastolic blood pressures that
were 1.9 mm Hg higher than did lead work-
ers with VDR bb, controlling for age, sex,
body mass index, antihypertensive medica-
tion use, cumulative alcohol consumption,
and blood lead levels (p = 0.09). After addi-
tion of 4-hr creatinine clearance to this
model, lead workers with VDR BB or Bb
genotypes had diastolic blood pressures that
were 2.5 mm Hg higher than lead workers
with the VDR bb genotype (p = 0.04). There
were no signiﬁcant associations of tibia lead,
blood lead, DMSA-chelatable lead, job dura-
tion, or ALAD genotype with diastolic blood
pressure (data not shown). ALAD and VDR
genotype did not modify the relations of
blood lead, tibia lead, DMSA-chelatable
lead, or age with diastolic blood pressure.
Predictors of hypertension. In crude
analysis, VDR genotype was associated with
hypertension status; lead workers with the
VDR B allele had a higher prevalence of
hypertension compared to lead workers with
the bb genotype [OR (95% CI) = 2.0 (1.1,
3.9); Table 4]. This association persisted after
adjustment, using logistic regression, for age,
sex, body mass index, tibia lead, and current
alcohol use [OR = 2.1 (1.0, 4.4)]. In this
model (Table 4), tibia lead was also a predictor
of hypertension status [OR = 1.005 (1.000,
1.011) for tibia lead as a continuous variable,
p = 0.05]. Blood lead, DMSA-chelatable lead,
and ALAD genotype were not associated with
hypertension status in the lead workers.
ALAD genotype, VDR genotype, and age
did not modify the relations of the three lead
dose measures with hypertension status. 
Discussion
In the lead workers under study, blood lead,
tibia lead, and DMSA-chelatable lead were
all predictors of systolic blood pressure; none
of these three lead dose measures was associ-
ated with diastolic blood pressure; and tibia
lead was the only predictor of hypertension
status. Taken as a whole, the associations of
the lead biomarkers with the blood pressure
measures and hypertension suggest that both
acute and chronic mechanisms may be
involved in the relations of lead exposure
and blood pressure (2,41). An interesting
new observation was that, on average, lead
workers with the VDR B allele, compared to
lead workers with the VDR bb genotype,
had higher systolic blood pressure, diastolic
blood pressure, and prevalence of hyperten-
sion, even after adjustment for important
confounding variables. Furthermore, VDR
genotype modified the relation of age with
systolic blood pressure; lead workers with the
B allele had earlier and larger elevations of
systolic blood pressure with increasing age at
the study visit. This suggests that release of
lead from bone stores, which may be inﬂu-
enced by VDR genotype (4), may play a role
in the observed blood pressure elevations. 
Our a priori expectation was that ALAD
and VDR genotypes would directly influ-
ence blood lead, tibia lead, and DMSA-
chelatable lead levels (3,4). We thus did not
expect that the two genotypes would modify
the relations among the lead biomarkers and
the blood pressure measures because, first,
the three lead biomarkers were measured
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Table 3. Linear regression modeling of systolic blood pressure, Korean lead workers, 1997–1999.a
Independent variable Units of coefﬁcient Coefﬁcient SE  p-Value Model r2
Model 1 0.32
Tibia lead mm Hg per µg/g 0.024 0.013 0.07
VDR, Bx vs. bb mm Hg 3.236 1.555 0.04
ALAD, 12 vs. 11 mm Hg 0.554 1.624 0.73
Model 2 0.32
Blood lead mm Hg per µg/dL 0.069 0.037 0.06
VDR, Bx vs. bb mm Hg 2.858 1.570 0.07
ALAD, 12 vs. 11 mm Hg 0.234 1.633 0.89
Model 3 0.31
DMSA-chelatable lead mm Hg per µg 0.006 0.003 0.04
VDR, Bx vs. bb mm Hg 2.720 1.581 0.09
ALAD, 12 vs. 11 mm Hg 0.737 1.653 0.66
Model 4 0.30
Tibia lead mm Hg per µg/g 0.017 0.014 0.22
Blood lead mm Hg per µg/dL 0.058 0.040 0.15
VDR, Bx vs. bb mm Hg 3.513 1.575 0.03
Model 5 0.29
Tibia lead mm Hg per µg/g 0.010 0.014 0.46
DMSA-chelatable lead mm Hg per µg 0.007 0.003 0.04
VDR, Bx vs. bb mm Hg 3.293 1.596 0.04
Model 6 0.32
VDR, Bx vs. bb mm Hg 2.411 2.212 0.27
Age mm Hg per year 0.259 0.061 < 0.01
Age2 mm Hg per year2 0.027 0.005 < 0.01
Age ×  VDR ×  Bx vs. bbb mm Hg per year 0.363 0.151 0.02
Age ×  VDR ×  Bx vs. bbb mm Hg per year2 0.001 0.015 0.94
aIn addition to variables listed under each model, models also controlled for age (linear and quadratic terms), sex, body
mass index, antihypertensive medication use, and cumulative lifetime drinks in current alcohol users [one glass of beer
or wine or one shot of distilled spirits, divided into quartiles (0–1,612 drinks, 1,613–4,160 drinks, 4,161–10,920 drinks, and
> 10,920 drinks)]. bCross-product terms between age (linear and quadratic terms) and VDR genotype. The relation of age
with systolic blood pressure in subjects with the VDR bb genotype is described by the coefﬁcients for age and age2. In
subjects with the VDR B allele, the coefﬁcients for the cross-product terms must be added to the respective coefﬁcients
for age and age2 to describe the relation of age with systolic blood pressure. This relation is plotted in Figure 1.directly, thus accounting for any genetic
inﬂuence, and, second, lead is not likely to be
inﬂuencing blood pressure via the ALAD or
VDR gene products. Our data suggest that
lead and VDR genotype are each indepen-
dently associated with blood pressure; VDR
modifies the toxicokinetics of lead, not the
direct inﬂuence of lead on blood pressure. 
The magnitude of the VDR genotype
effect was relatively large. On average and
after controlling for covariates, subjects with
the B allele, mainly heterozygotes, had sys-
tolic blood pressures that were approxi-
mately 2.7–3.7 mm Hg higher than those of
lead workers with the bb genotype; and had
a 2-fold increased risk of hypertension. The
magnitude of the VDR association was
largest when blood urea nitrogen  was added
to the regression models of systolic blood
pressure, raising the possibility that lead, the
VDR, and the kidney independently
contribute to elevations in blood pressure.
Prior studies of bone mineral density suggest
that the B allele has a dose effect, in that the
influence of the allele increases with more
copies (25,40,42,43). If this is the case with
blood pressure, then the average effect of the
B allele may be even larger in populations
with larger numbers of BB homozygotes.
The BB genotype has a prevalence of 7–32%
in Caucasians (25), but only 0.5% of the
Korean lead workers had that genotype. 
A large body of literature reveals that the
ALAD genotype modiﬁes the toxicokinetics
of lead (5); we were thus interested in evaluat-
ing whether these toxicokinetic modiﬁcations
could influence lead’s effect on blood pres-
sure. Human ALAD is encoded by a single
gene on chromosome 9p34 (6,7). The preva-
lence of the ALAD2 allele is approximately
10% in Asians and 20% in Caucasians
(8–10). Subjects who have at least one copy
of the ALAD2 allele, compared to subjects
with none, have higher blood lead levels
(8–10), lower DMSA-chelatable lead levels
(11), lower plasma aminolevulinic acid levels
(12), a larger difference between trabecular
and cortical bone lead levels (13), higher
blood urea nitrogen and serum creatinine
levels (13), less efﬁcient uptake of lead into
bone, especially trabecular (14), lower zinc
protoporphyrin levels for given levels of
blood lead (15), and lower urinary calcium
and creatinine levels (16). ALAD has been
identiﬁed as a principal lead-binding protein,
and the proportion of lead bound to ALAD
was greater for subjects with ALAD2 (17).
These observations suggested to us that
ALAD genotype could modify the inﬂuence
of lead on blood pressure, but the current
data did not support this hypothesis. It is
possible that in populations with a higher
prevalence of the ALAD2 allele and with dif-
ferent distributions of other important genes
such as VDR, ALAD genotype may modify
the inﬂuence of lead on blood pressure and
other health outcomes.
A second gene that has recently been the
focus of lead research is that for VDR,
located at chromosome 12cen-12 (44). Most
studies of the VDR gene have focused on the
BsmI polymorphism and the three resulting
genotypes termed bb, Bb, and BB (although
the FokI polymorphism has been receiving
increasing attention). Study subjects (mainly
women) with the BB genotype have bone
mineral densities up to 10–15% lower than
subjects with the bb genotype (25,40,42,
43,45), with an overall difference across stud-
ies of 2–2.5% reported in a recent meta-
analysis (25). We recently reported that
subjects with the B allele had larger tibia lead
concentrations with increasing age and lower
tibia lead concentrations with increasing
duration since last exposure to lead than did
subjects without the B allele (4). In another
study of VDR genotype in lead workers, of
the subjects reported here, lead workers with
the VDR B allele had signiﬁcantly (p < 0.05)
higher blood lead levels (on average, 4.2
µg/dL), chelatable lead levels (on average,
37.3 µg), and tibia lead levels (on average,
6.4 µg/g) than did workers with the VDR bb
genotype, controlling for covariates (3). Now
we provide evidence that VDR genotype also
had a direct effect on blood pressure and
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Figure 1. Effect modiﬁcation by VDR genotype on the relation between age and systolic blood pressure,
controlling for age (linear and quadratic terms), sex, body mass index, antihypertensive medication use,
and cumulative lifetime alcohol dose (divided into quartiles), in 794 Korean lead workers. The solid line
and “1” are for subjects with the VDR B allele; the dashed line and “0” are for subjects with the VDR bb
genotype. This is a plot of the results of model 6, Table 3.
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Table 4. Associations of VDR genotype with hypertension status in Korean lead workers.
Hypertension, n (%)a Crude OR  Adjusted OR 
VDR genotype Yes No  Total  (95% CI)b (95% CI)c
bb 64 (9.0)  645 (91.0) 709 (100) 1.0 1.0
Bb or BB 15 (16.9) 74 (83.1) 89 (100) 2.0 (1.1, 3.9) 2.1 (1.0, 4.4)*
Total 79 (9.9) 719 (90.1) 798 (100)
aHypertension deﬁned as systolic blood pressure > 160 mm Hg or diastolic blood pressure > 96 mm Hg or currently
taking medications for high blood pressure. bSubjects with VDR bb are the reference group. cAdjusted for age, sex,
body mass index, tibia lead, and current alcohol use. *p < 0.05.modified the elevations in blood pressure
associated with age. VDR genotype did not
modify the relations of the lead dose mea-
sures with blood pressure. 
The most critical role of the active form
of vitamin D, 1,25-dihydroxyvitamin D3
[1,25(OH)2D3], is the activation of genes
involved in intestinal calcium transport (46).
1,25(OH)2D3 binds to the VDR, and the
activated VDR regulates the rate of tran-
scription of vitamin D-responsive genes
(46). The VDR is found in intestine, bone,
kidney, parathyroid glands, hematopoietic
tissues, immune tissues, muscle, heart, skin,
pancreas, and other sites, and 1,25(OH)2D3
has recognized actions in all these tissues
(46). Several genetic polymorphisms have
been found within the VDR, and these have
been implicated to influence bone mineral
density (25), the risk of primary hyper-
parathyroidism (47), parathyroid hormone
levels and tubular resorption of phosphate
(48), the response of psoriasis to vitamin D
therapy (49), urinary calcium excretion and
the risk of nephrolithiasis (50), and serum
osteocalcin levels (40). 
The links among calcium, lead, and
blood pressure have been increasingly recog-
nized. Calcium supplementation lowers
blood pressure (51); several studies have
reported that increased dietary calcium,
especially from dairy products, is associated
with lower blood pressure (52–54); and
lower vitamin D intake has been associated
with higher blood pressure in women (55).
Moderate lead levels can cause elevations in
serum 1,25(OH)2D3 and parathyroid hor-
mone levels (56,57). Lower dietary intake of
calcium has been associated with higher
serum parathyroid levels, and women with
these higher levels had significantly higher
blood pressures (58). 
The functional significance of the BsmI
polymorphism is unclear because it is not
located at exon–intron boundaries, would
not inﬂuence the structure of the VDR, and
is not known to produce splicing errors; and
recent in vitro studies have not demon-
strated differences in VDR expression or
cellular responsiveness to vitamin D treat-
ment by genotype (24,59). This suggests
that the BsmI polymorphism may be in
linkage disequilibrium with another func-
tional variant at the VDR locus or with a
nearby bone metabolism gene (24). It is not
known how the VDR polymorphism could
inﬂuence blood pressure, but the links among
lead, calcium, VDR, and blood pressure
would clearly suggest biologic plausibility.
An important question is whether selec-
tion bias could account for the study results.
Evidence from this study and prior ones
(3,8) suggests that there may be selective
movement of workers, by gentoypes, out of
lead-using workplaces. For selection by
genotype or other factors to account for the
observed association of the VDR B allele
with blood pressure and hypertension, such
a factor would have to increase the preva-
lence of VDR B and elevated blood pressure.
While this type of selection is possible, it
requires a complex interplay of a number of
factors. First, there would have to be a
behavioral response to lead exposure, per-
haps mediated by development of symp-
toms, that would motivate persons to leave
the workplace. Second, the behavioral
response would have to be associated with
both the VDR B allele and elevated blood
pressure. We think this complex model of
selection bias is unlikely to explain the asso-
ciation we observed. However, longitudinal
analysis is less susceptible to these biases, and
will be used in the future, after the comple-
tion of data collection, to evaluate these asso-
ciations further.
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